ClinicalTrials.gg
Not yet recruitingNCT07942636Updated Nov 17, 2026

EMST 150 Training in Mild-Moderate OSA

An interventional study of Expiratory Muscle Strength Training Device (EMST 150) and Oropharyngeal Myofunctional Therapy (MT) in Obstructive Sleep Apnea, sponsored by University Hospitals Cleveland Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospitals Cleveland Medical Center · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 754 studies in Sleep Apnea, Obstructive with a site in United States — 127 open to participants now, 161 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Planned enrollment
447th of 595
20 · median 49
Started
2026
with 41 others
No phase
411 of 754
67 open now
Primary completion
2027-12
later than 115 of 160 live
Registered
754th of 754
by date

Among the 754 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 447th largest by planned enrollment of the 595 interventional ones that give a count, is one of 42 that started in 2026, is one of 411 with no phase, reaches primary completion later than 115 of the 160 other live ones, and was the 754th registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

127 of the 754 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

122 more — sign in →

All 127 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

Obstructive Sleep Apnea is a condition in which the upper airway repeatedly becomes blocked during sleep, often due to weakness or collapse of the upper airway throat muscles. The purpose of this study is to evaluate whether combining a handheld breathing device (Expiratory Muscle Strength Training (EMST 150)) with structured, speech-language pathology-Guided mouth and throat exercises can help strengthen the muscles that keep the airway open, reduce snoring, and reduce sleep apnea severity while improving overall sleep quality. Participation in this study will last about 3 months. This includes a 5-week home breathing exercise program, two in-person clinic visits (at the beginning of the study and at Month 3), and two short phone check-ins.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • Home sleep apnea testing
  • Polysomnography (PSG)
  • Muscle function
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Mild-to-Moderate OSA (5\<AHI\<30 events/hour)
  • Patient willingness and physical capability to perform threshold-based respiratory exercises and daily oral myofunctional exercises.
  • Documented failure, intolerance (defined as regular use \< 4 hours/night), or patient refusal of standard therapies, including Continuous Positive Airway Pressure (CPAP) and surgical interventions.

Exclusion criteria

Exclusion Criteria:

  • Severe OSA (AHI>30 events/hour)
  • Active asthma, severe or poorly controlled asthma with low symptom perception, or severe (COPD)
  • Uncontrolled hypertension, defined as resting systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening, or any change in antihypertensive medication within the past 30 days, or significant cardiovascular disease.
  • Recent esophageal surgery, recent abdominal surgery, or presence of an abdominal hernia.
  • History of spontaneous pneumothorax, or incomplete recovery/healing following traumatic pneumothorax or rib fracture.
  • History of lung transplantation or lung resection.
  • Current tracheostomy or unhealed tracheostomy stoma.
  • Presence of a cerebrospinal fluid (CSF) drain or active intracranial pressure monitoring.
  • Active epistaxis (frequent/severe nosebleeds) or active hemoptysis within the past 30 days.
  • Tympanic membrane perforation (ruptured eardrum) or active inner/middle ear pathology.
  • Unrelated or uncontrolled gastroesophageal reflux disease (GERD).
  • Known or suspected pregnancy.
  • Active use of CPAP, mandibular advancement device (MAD), or hypoglossal nerve stimulation (HGNS) during the study period.
  • Any acute medical condition or clinical situation where generating intrathoracic, intro-abdominal, or intracranial pressure (similar to Valsalva maneuver) is clinically .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Participants with Obstructive Sleep Apnea (OSA)

    Adult participants diagnosed with mild-to-moderate obstructive OSA.

    Device: Expiratory Muscle Strength Training Device (EMST 150) · Behavioral: Oropharyngeal Myofunctional Therapy (MT)

Interventions

  • DeviceExpiratory Muscle Strength Training Device (EMST 150)

    Participants utilize the EMST 150 device to strengthen expiratory and upper airway musculature. During training, participants inhale deeply and exhale forcefully through the mouthpiece again calibrated resistance while maintaining an airtight lip seal to overcome the target threshold pressure.

  • BehavioralOropharyngeal Myofunctional Therapy (MT)

    Participants perform structured oral motor exercises : * Lingual maneuvers * Soft palate and velopharyngeal exercises * Facial and buccinator muscle conditioning to reinforce nasal breathing.

06

What researchers measure

Primary outcomes

  1. Change in Sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire that evaluates overall sleep quality and disturbances over a one-month time interval. With higher scores indicating poor sleep quality.

    Time frame: Baseline, 3 months

  2. Change in Daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS)

    The Epworth Sleepiness Scale (ESS) is a short, self-administered questionnaire used to measure a person's general level of daytime sleepiness and likelihood of dozing off in everyday situations. Scored on a scale from 0 would never doze, to 3 high chance of dozing.

    Time frame: Baseline, 3 months

  3. Snore score as measured by smartphone application monitoring.

    Smartphone application monitoring (Snorelab) will be used to track longitudinal acoustic changes in nightly snoring. The application analyzes breathing sounds to compute aggregate acoustic metrics.

    Time frame: Up to 3 months

  4. Percentage of snoring sleep time as measured by smartphone application monitoring.

    Smartphone application monitoring (Snorelab) will be used to track longitudinal acoustic changes in nightly snoring. The application analyzes breathing sounds to compute aggregate acoustic metrics.

    Time frame: Up to 3 months

  5. Noise intensity in decibels as measured by smartphone application monitoring.

    Smartphone application monitoring (Snorelab) will be used to track longitudinal acoustic changes in nightly snoring. The application analyzes breathing sounds to compute aggregate acoustic metrics.

    Time frame: Up to 3 months

  6. Change in Isometric maximal tongue pressure (kPa) as measured by the Iowa Oral Performance Instrument (IOPI)

    The Iowa Oral Performance Instrument (IOPI) is a portable, evidence-based medical device used to objectively measure, document, and train lip and tongue strength and endurance. The device digitally records maximum isometric pressure in kilopascals

    Time frame: Baseline, 3 months

  7. Change in tongue muscle endurance as measured by time in seconds sustained at 50% maximal pressure.

    Time in seconds sustained at 50% maximal pressure.

    Time frame: Baseline, 3 months

  8. Change in Apnea-Hypopnea Index (AHI)

    The apnea-hypopnea index (AHI) is the average number of breathing pauses (apneas) and shallow breathing events (hypopneas) that occur per hour of sleep, with higher scores indicating greater sleep apnea severity.

    Time frame: Baseline, 3 months

  9. Change in Maximum Expiratory Pressure (MEP)

    MEP is the highest positive pressure generated by a person during a forced exhalation against a blocked airway. It measures the strength of the expiratory muscles, including the abdominal and internal intercostal muscles, and helps evaluate cough efficiency and neuromuscular function. Lower scores indicate generalized respiratory muscle weakness, chronic obstructive pulmonary disease (COPD), or neuromuscular conditions like myasthenia gravis or Guillain-Barré syndrome.

    Time frame: Baseline, 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 508 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 12 months is below that.

Counting every sponsor, half of 624 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942636
Responsible party
Thomaz Fleury Curado (Division Chief, University Hospitals Cleveland Medical Center) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Thomaz Fleury Curado, MD
Contact
thomaz.fleurycurado@uhhospitals.org
216-844-1716
Thomaz Fleury Curado, MD
principal investigator · University Hospitals Cleveland Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion